Tirzepatide for the treatment of patients with type 2 diabetes

Technology appraisal committee A [1st August 2023]

Chair: Radha Todd

Lead team: Alan Thomas, Fiona MacPherson Smith, Min Ven Teo

External assessment group: Kleijnen Systematic Reviews (KSR) Ltd. in collaboration with Erasmus University Rotterdam (EUR) and Maastricht University Medical Center (UMC+)

Technical team: Giacomo De Guisa, Ewa Rupniewska, Janet Robertson

Company: Eli Lilly

© NICE 2023. All rights reserved. Subject to Notice of rights.
Tirzepatide is not recommended, within its marketing authorisation, for treating type 2 diabetes alongside diet and exercise in adults when it is insufficiently controlled:

• alone when metformin cannot be taken because of intolerance or contraindications, or
• with other antidiabetic drugs.
## ACM1 resolved issues

<table>
<thead>
<tr>
<th>Issue</th>
<th>Committee Resolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mismatch between scope and decision problem: line of therapy and comparators</td>
<td>Accepted GLP-1 RAs are relevant comparators</td>
</tr>
<tr>
<td>Mismatch between decision problem and evidence: line of therapy + prior oral antidiabetic drug intensity</td>
<td>Noted discrepancy, which contributed to decision uncertainty</td>
</tr>
<tr>
<td>Mismatch between tirzepatide administration in clinical practice and trial</td>
<td>Acknowledged this was the best evidence available</td>
</tr>
<tr>
<td>Modelling of long-term risk factor progression</td>
<td>Accepted company’s approach</td>
</tr>
<tr>
<td>Only one criterion (HbA1c threshold) for treatment discontinuation/intensification applied in the model</td>
<td>No concerns raised</td>
</tr>
<tr>
<td>Not all adverse events incorporated for all treatments</td>
<td>Accepted company’s approach</td>
</tr>
<tr>
<td>Potentially inappropriate probabilistic sensitivity analyses</td>
<td>Noted mean ICERs should be accurate</td>
</tr>
</tbody>
</table>

**Abbreviations:** HbA1c, glycated haemoglobin; GLP-1 RA, Glucagon-Like Peptide-1 receptor agonist; ICER, incremental cost-effectiveness ratio.
### ACM1 key issues for discussion today

<table>
<thead>
<tr>
<th>Issue</th>
<th>Provided?</th>
<th>ICER impact</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NMA results uncertain:</strong> scenario analysis based on direct comparison between semaglutide and tirzepatide would be useful</td>
<td>Yes</td>
<td>Small</td>
</tr>
<tr>
<td><strong>Economic model verification:</strong> EAG unable to fully scrutinise the model; full deterministic one-way sensitivity analyses, further info on model validation and comparison with other recognised diabetes models would be useful</td>
<td>Yes</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Micro- and macrovascular complications:</strong> Company’s model averaging approach uncertain; scenario analysis using single-risk prediction models would be useful</td>
<td>Yes</td>
<td>Small</td>
</tr>
<tr>
<td><strong>Treatment intensification:</strong> GLP-1 RAs use in clinical practice may deviate from NICE recommendations; scenario analysis assuming treatment is intensified by adding insulin to tirzepatide and GLP-1 RAs would be useful</td>
<td>Yes</td>
<td>Small</td>
</tr>
<tr>
<td><strong>Baseline utility value:</strong> lower value preferred for decision making</td>
<td>Yes</td>
<td>Small</td>
</tr>
<tr>
<td><strong>Combining disutilities:</strong> multiplicative method preferred, unless additive method adequately justified</td>
<td>Yes</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

Abbreviations: GLP-1 RA, Glucagon-Like Peptide-1 receptor agonist; NMA, network meta-analysis.

*a* Model averaging: estimates the risk in a range of simulation populations, combining risk equations, and automatically weighing the risk equations for different populations.
Background on type 2 diabetes mellitus

- Chronic metabolic disorder: reduced tissue sensitivity to insulin (known as insulin resistance) → loss of endogenous insulin production → elevated blood glucose levels (hyperglycaemia)
- UK prevalence of T2D is rising, due to increasing prevalence of obesity
- If not managed effectively, it can lead to devastating, life-changing complications

Technology details: tirzepatide (Mounjaro, Eli Lilly)

| Marketing authorisation | • Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise  
| | • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications  
| | • in addition to other medicinal products for the treatment of diabetes |
| Mechanism of action | • Dual receptor agonist of GIP and GLP-1 hormones which act to stimulate insulin secretion |
| Administration | • Weekly subcutaneous injection |
| Price | • Proposed list price per pack of 4 pre-filled single-dose autoinjector pen devices 5 mg, 10 mg and 15 mg: XXXXXXXX, respectively; for 12 months of treatment: XXXXXX, respectively  
| | • Note: price will be disclosed when guidance is published, XXXXXXXXXXXX |

Abbreviations: GIP, Glucose-Dependent Insulinotropic Polypeptide; GLP-1, Glucagon-Like Peptide-1; T2D, type 2 diabetes.
### Treatment pathway and proposed positioning of tirzepatide

Depends on HbA1c level, cardiovascular risk, kidney function and other factors. Treatment intensified when HbA1c not controlled or change in cardiovascular risk/status.

<table>
<thead>
<tr>
<th>1st line</th>
<th>Chosen individually, based on multiple factors and patients circumstances, including HbA1c level, cardiovascular risk and kidney function; generally includes:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• metformin (not at high CVD risk)</td>
</tr>
<tr>
<td></td>
<td>• metformin plus SGLT2 inhibitor (chronic heart failure or established atherosclerotic CVD&lt;sup&gt;a&lt;/sup&gt;)</td>
</tr>
<tr>
<td></td>
<td>• DPP-4 inhibitor, pioglitazone, sulfonylurea or SGLT2 inhibitor (if metformin contraindicated)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2nd line</th>
<th>Treatment intensified when:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• person's HbA1c not controlled below individually agreed threshold: switching to or adding DPP-4 inhibitor, pioglitazone, sulfonylurea or SGLT2 inhibitor</td>
</tr>
<tr>
<td></td>
<td>• person develops CVD or a high risk of CVD (switching to or adding SGLT2 inhibitor)</td>
</tr>
</tbody>
</table>

| 3rd & further lines | • Insulin-based therapy (with or without other drugs): when dual therapy has not continued to control HbA1c to below the person's individually agreed threshold |
|                    | • GLP-1 mimetic treatments: if triple therapy with metformin and 2 other oral drugs is not effective, not tolerated or contraindicated<sup>b</sup>; for adults with type 2 diabetes who have: |
|                    | • BMI of ≥35<sup>c</sup> kg/m<sup>2</sup> and specific psychological or other medical problems associated with obesity |
|                    | • BMI <35 kg/m<sup>2</sup> and for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity related comorbidities. |

### Relevance comparators: GLP-1 mimetics used in NHS practice

<sup>a</sup> SGLT2 inhibitor can also be considered for people at high risk of CVD; <sup>b</sup> switching one of the drugs to a GLP-1 mimic; <sup>c</sup> adjusted accordingly for people from Black, Asian and other minority ethnic groups; Source: NICE guideline 28. Abbreviations: CVD, cardiovascular disease; DPP-4, Dipeptidyl-Peptidase 4; GLP-1, glucagon-like peptide-1; HbA1c, Glycated Haemoglobin SGLT2, Sodium-Glucose Co-Transporter-2. 

---

Tirzepatide’s marketing authorisation spans entire treatment pathway.

Company positions tirzepatide as alternative to GLP-1 mimetics.
Clinical effectiveness data: SURPASS 2-5 trials

• Randomised, multicentre phase 3 trials; open-label (SURPASS-2 to -4) or placebo-controlled (SURPASS-5)
• Included people with HbA1c of ≥7.0% (≥7.5% in SURPASS-4) to ≤10.5%; stable weight for 3 months and BMI ≥25 kg/m² (≥23 kg/m² in SURPASS-5)
• Excluded people receiving triple therapy (except SURPASS-4 – but only 33% patients had it)
• People were randomised to their maximum dose of tirzepatide (note: treatment would be titrated as needed in clinical practice)
• Comparators (prior/background therapy):
  • SURPASS-2: semaglutide (metformin);
  • SURPASS-3: insulin degludec (metformin +/- SGLT-2 inhibitor);
  • SURPASS-4: insulin glargine (≥1 to ≤3 oral antidiabetic drugs);
  • SURPASS-5: placebo (insulin glargine +/- metformin).
• Tirzepatide (all doses) showed statistically significant reductions in HbA1c and weight vs comparators
  • Higher tirzepatide doses→higher weight reductions (dose-dependent effect less pronounced for HbA1c)

Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; SGLT-2, Sodium-Glucose Co-Transporter-2.
Clinical effectiveness data: network meta-analysis

- Included RCTs in people on 1-2 oral antidiabetic drugs → misaligned with decision problem
- Studies varied greatly in prior treatment and patient characteristics → results uncertain
- Tirzepatide showed significantly greater reductions in HbA1c and BMI vs GLP-1 RAs – but size of treatment effect uncertain

Tirzepatide 10 mg vs comparators (example)
Forest plots (median difference [95% CrI]; random effects model) for change from baseline in:

- HbA1c (%)
- Body mass index (kg/m²)

Abbreviations: BMI, body mass index; CrI, credible interval; GLP-1 RA, Glucagon-Like Peptide-1 receptor agonist; HbA1c, glycate haemoglobin; RCT, randomised controlled trial.
Company’s model overview

PRIME T2D model: discrete time event, patient-level simulation (developed in Java)

Technology affects costs by:
• Additional treatment costs
• Reductions in diabetes-related complication costs (especially cardiovascular events avoided)

Technology affects QALYs by:
• Reductions in diabetes-related complications
• Reductions in BMI

Complication Risk models informed by Risk factors including HbA1c, BMI and SBP

Note: Model structure from Company response to EAG report, May 2023; *Model averaging used in controller; †, complications with increased risk of mortality in year of complication onset and subsequent years; ‡, complications with increased risk of mortality associated with history of this complication

Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; QALYs, quality-adjusted life years; QoL, quality of life; RNG, random number generator; SBP, systolic blood pressure; SPSL, severe pressure sensation loss.
Consultation comments
ACD consultation responses – summary

Consultation comments
Comments received from:
• Eli Lilly (the company)
• Diabetes UK (patient organisation)
• Association of British Clinical Diabetologists (ABCD; professional organisation)
• Web comment (competitor company employee)
ACD consultation responses – Diabetes UK

• Would be supportive of a positive tirzepatide recommendation due to strong supportive trial data
• Concerned that a negative recommendation will lead to fewer and less effective treatment options for people with T2D
• Tirzepatide increases treatment options where other medications may not be viable due to existing contraindications
• There is a current shortage of GLP-1 RAs in the UK which is unlikely to be resolved until mid-2024
  • Latest guidance from NHS England and the Department of Health and Social Care is not to issue any new prescriptions of GLP-1 RAs until the shortage is resolved
  • A positive tirzepatide recommendation would increase the options for prescribers and potentially provide solutions to the GLP-1 RA shortage

Abbreviations: ACD, appraisal consultation document; GLP-1 RA, Glucagon-Like Peptide-1 receptor agonist; T2D, type 2 diabetes.
ACD consultation responses – ABCD

- All GLP-1 RAs have a broad licence but have been allocated a niche and late positioning in current NICE guidance. Therefore, it is harsh to criticise the company for not applying for use in the totality of tirzepatide’s licenced indication. Also, for this reason, the global phase 3 clinical trial programme of tirzepatide does not focus on the patient cohort of greatest interest to the committee.

- Tirzepatide is directly compared to the most potent GLP-1 RA currently available (semaglutide) in the SURPASS-2 trial (semaglutide’s potency is supported by head-to-head clinical trial directly comparing comparators).

- Regrets that issues with model validation could not be resolved ahead of first committee meeting.
ACD consultation responses – Web comment (Pharma)

Unclear if company’s SLRs includes all available evidence for tirzepatide:
• Sattar et al. 2022 reports data from a pre-specified cardiovascular meta-analysis and post-hoc safety analysis across one phase 2 and five 3 trials (prospectively collected and centrally adjudicated MACE events from the trials)
• SURMOUNT-2 and SURMOUNT-CN were not included in the company’s submission

Unclear if resource utilisation associated with prolonged titration/up-titration of tirzepatide has been considered:
• Slower up-titration of tirzepatide would be more resource intensive for NHS
• If patients are not moved on to maintenance doses (i.e. remain on non-maintenance doses) due to gastrointestinal tolerability or blood glucose optimisation, further NHS resources would likely be required

Concerns with modelling of adverse events (only nausea included; hypoglycaemic rates only for basal insulin)
• Diarrhoea is very common with GLP-1 RAs and tirzepatide\(^a\)
• GLP-1 RAs are known to increase the risk of hypoglycaemia-related adverse events when used in combination with sulphonylurea or insulin, e.g. in SURPASS 5, all doses of tirzepatide added on top of insulin glargine, had higher rates of hypoglycaemia than placebo\(^b\)

---

\(^a\) In SURPASS 2, the rates of diarrhoea were 13.2%, 16.4%, 13.8% and 11.5%, tirzepatide 5 mg, 10 mg and 15 mg, and semaglutide 1 mg, respectively

\(^b\) proportion of patients experiencing hypoglycaemia were 15.5%, 19.3%, 14.2% and 12.5% for tirzepatide 5 mg, 10 mg, 15 mg and placebo, respectively

Abbreviations: ACD, appraisal consultation document; GLP-1 RA, Glucagon-Like Peptide-1 receptor agonist; MACE, major adverse cardiovascular event; SLR, systematic literature review.
ACD consultation responses – Web comment (Pharma)

Comment
• Sattar et al. 2022 reports data from a pre-specified cardiovascular meta-analysis and post-hoc safety analysis across one phase 2 and five 3 trials (prospectively collected and centrally adjudicated MACE events from the trials)

ACM1:
• No excess risk for CV events with tirzepatide, based on meta-analysis of positively adjudicated major adverse cardiovascular events (MACE) in SURPASS trials
• Further data on CV outcomes expected from SURPASS-CVOT trial in 2025

Comment
• Diarrhoea is very common with GLP-1 RAs and tirzepatide

ACM1:
• Incorporating rates of diarrhoea from NMA showed modest QALY differences from base case analysis
Note: Company submitted updated scenario analysis in addendum to draft guidance consultation – minor impact on ICER (higher than base case)

---

a Source: company response to EAG report and ACM slide 34. b Source: ACM1 slide 38 and company clarification response.
Abbreviations: CV, cardiovascular; ICER, incremental cost-effectiveness ratio; MACE, major adverse cardiovascular event; NMA, network meta-analysis; QALY, quality-adjusted life year; T2D, type 2 diabetes.
ACD consultation responses – Web comment (Pharma)

**Comment**
- SURMOUNT-2 and SURMOUNT-CN were not included in the company’s submission

**Company rationale**
- SURMOUNT trials are recent studies in a different indication (weight loss); not relevant for this appraisal
- Only SURMOUNT-2 included patients with diabetes, although this trial was specifically designed to assess weight reduction as the primary outcome rather than HbA1c reduction; T2D was secondary to the trial
- SURMOUNT-2 would not have been included in the NMA for the current appraisal, as the definition of background therapies permitted is not directly relevant to the current decision problem
- SURMOUNT-2 data published on 26th June 2023; SURMOUNT-CN not yet published

**EAG comments**
- Substantial differences between SURMOUNT-2 and SURPASS 2-5 trials – direct comparison not advisable
- Key difference: SURMOUNT-2 allowed change in concomitant medication during trial (SURPASS trials not)
- Participants in SURMOUNT-2 were not required to have inadequate glycaemic control on with metformin monotherapy (with or without other antidiabetic medication) on entry, unlike in SURPASS 2-4 trials
- People treated with insulin were excluded from SURMOUNT-2
- Differences in baseline characteristics: duration of diabetes (years) and the level of HbA1c (% and mmol/mol) was less in SURMOUNT-2, while weight (Kg) and BMI (% and category) was higher.
## Comparison between: SURPASS-2, -5 and SURMOUNT-2

<table>
<thead>
<tr>
<th></th>
<th>SURPASS-2</th>
<th>SURPASS-5</th>
<th>SURMOUNT-2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Design</strong></td>
<td>Randomised, multicentre phase 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Open-label</td>
<td>Double-blind</td>
<td></td>
</tr>
<tr>
<td><strong>Population</strong></td>
<td>Patients with T2D, who had inadequate glycaemic control with metformin monotherapy</td>
<td>Patients with T2D, with background therapy of insulin glargine with or without metformin</td>
<td>Patients (aged ≥18 years) with a body mass index of 27 kg/m² or higher and glycated haemoglobin (HbA1c) of 7–10%</td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
<td></td>
<td>Tirzepatide</td>
<td></td>
</tr>
<tr>
<td><strong>Comparator</strong></td>
<td>Injectable semaglutide 1 mg</td>
<td>Placebo</td>
<td></td>
</tr>
<tr>
<td><strong>Background therapy</strong></td>
<td>Metformin</td>
<td>Insulin glargine ± metformin</td>
<td>Any oral glycaemic lowering agent (except DPP-4 inhibitors and GLP-1 RAs)*</td>
</tr>
<tr>
<td><strong>Primary outcomes</strong></td>
<td>Mean change in HbA1c values from baseline to 40 weeks for tirzepatide 10 mg and 15 mg</td>
<td>Mean change in HbA1c values from baseline to 40 weeks</td>
<td>Mean percent change from randomisation in body weight and percentage of participants who achieve ≥5% body weight reduction</td>
</tr>
</tbody>
</table>

*Could be changed during trial

Abbreviations: CVD, cardiovascular disease; DPP-4, Dipeptidyl Peptidase 4; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; SGLT2i, Sodium-Glucose Co-Transporter-2 inhibitor; SU, sulphonylurea; T2D, type 2 diabetes.
Key results: SURMOUNT-2

<table>
<thead>
<tr>
<th>N</th>
<th>312</th>
<th>311</th>
<th>315</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Change in HbA1c, percentage</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline to 72 weeks</td>
<td>-2.07</td>
<td>-2.08</td>
<td>-0.51</td>
</tr>
<tr>
<td>Estimated treatment difference from placebo (95% CI) at 72 weeks</td>
<td>-1.55* (-1.74, -1.37)</td>
<td>-1.57 * (-1.76, -1.37)</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Body weight change from baseline, percentage (kg)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline to 72 weeks</td>
<td>-12.8</td>
<td>-14.7</td>
<td>-3.2</td>
</tr>
<tr>
<td>Estimated treatment difference from placebo (95% CI) at 72 weeks</td>
<td>-9.6* (-11.1, -8.1)</td>
<td>-11.6* (-13, -10.1)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*\(p<0.0001\) vs. comparator

Abbreviations: CI, confidence interval; HbA1c, glycated haemoglobin; T2D, type 2 diabetes.

Is it appropriate that SURMOUNT-2 was excluded from company submission? What may be the impact of excluding it?
ACD consultation responses – Company
Provided additional analyses and justification for approaches

Summary of company response to ACD – company provided:
• Results of analysis run in CORE Diabetes Model
• Validation of PRIME T2D model against other models and published studies
• One-way deterministic sensitivity analyses
• Justification for using model averaging approach for estimating risk of micro- and macrovascular complications & justification for risk equations chosen
• Justification for additive approach when combining disutilities
• Scenario analyses for:
  • SURPASS-2 results directly comparing tirzepatide to semaglutide
  • Insulin being added to GLP-1 RA therapy or tirzepatide (instead of switching)
  • Using only UKPDS risk equations to predict the risk of micro- and macrovascular complications
  • Using lower baseline utility values for people with T2D
  • Using a multiplicative approach to combining disutilities

Note: Company responses to ACD also included XXXXXXXXXXXXXXXXXXXX
Note: The company agreed with NICE that additional scenario and sensitivity analyses can focus mainly on tirzepatide 10mg vs semaglutide 1mg for illustration of the impact on ICERs

Abbreviations: ACD, appraisal consultation document; GLP-1 RA, Glucagon-Like Peptide-1 receptor agonist; ICER, incremental cost-effectiveness ratio; T2D, type 2 diabetes; UKPDS, UK Prospective Diabetes Study.
Key issue: Uncertainty around network meta-analysis (NMA)

Committee comments at ACM1
• Studies included in NMA varied greatly in prior treatment and patient characteristics: results uncertain
• Direct comparison between tirzepatide and semaglutide possible based on SURPASS-2 results → scenario analysis based on this data may be useful for decision making, despite misalignment with company’s target population in terms of prior treatments received

Company response to ACD
• Scenario analysis provided using cohort characteristics and treatment effects from the SURPASS-2 trial
• For all tirzepatide doses, ICERs were <£20,000 per QALY gained vs semaglutide 1.0mg, and slightly lower than the base case ICERs

EAG comments
• An overview of input parameters that were modified for this scenario (as well as updated parameter values) would have helped understanding of this scenario

Abbreviations: ACD, appraisal consultation document; ICER, incremental cost-effectiveness ratio; NMA, network meta-analysis; QALY, quality-adjusted life year.
Key issue: Economic model verification

Company provided additional information and analyses to validate model

Committee comments at ACM1

- Hypothetically, company’s PRIME T2D model might be an improvement over other diabetes models
- EAG was not able to scrutinise the model to the usual rigorous standard because of model complexity and non-standard software
- Could not be confident that the company cost-effectiveness results were accurate
- Confidence could be improved by:
  - Deterministic one-way sensitivity analyses on the full set of model parameters
  - Comparison with cost-effectiveness analysis run in the CORE Diabetes Model or UKPDS outcomes model

Company response to ACD – company provided

- One-way sensitivity analyses for key model inputs for tirzepatide 10 mg vs semaglutide 1.0 mg
- Validation of PRIME T2D model against other models and published studies
- Cost-effectiveness results run in CORE Diabetes Model

Abbreviations: ACD, appraisal consultation document; T2D, type 2 diabetes; UKPDS, UK Prospective Diabetes Study.
Deterministic one-way sensitivity analyses (1)
ICERs <£20,000 per QALY for 224 out of 232 analyses

Company:
- Two scenarios where semaglutide was dominant involved substantial changes to the HbA1c profile to favour semaglutide
- High ICERs were observed when certain risk factors were held constant over time for semaglutide and allowed to increase for tirzepatide
- These were not considered a reflection of a possible clinical scenarios

Abbreviations: HbA1c, glycated haemoglobin; ICER, incremental cost effectiveness ratio; LDL, low density lipoprotein; QALY, quality-adjusted life year; QoL, quality of life; SBP, systolic blood pressure; UKPDS, UK Prospective Diabetes Study
Deterministic one-way sensitivity analyses (2)
Key ICER drivers noted by EAG

EAG comments – one-way sensitivity analyses
• Risk factors (HbA1c, SBP, LDL, HDL), the utility decrement on insulin years 2+, insulin treatment costs, hypoglycaemia rate and treatment costs can have a substantial impact on the estimated ICER
• One-way sensitivity analyses were predominantly performed using alternative assumptions (e.g. assuming 10% increase or decrease rather than the estimated standard error) of the specific parameter of interest
• Individual parameters of the risk models (including the UKPDS risk factor progression) were not included in the one-way sensitivity analyses
Model verification against other models/published studies (1)

Company response to ACD
- Validation analysis compared projections using PRIME T2D Model with published results from a broad range of studies in T2D populations, including UK cohort studies, CVOTs and studies in South East Asian populations
- All RMSD values (a measure of difference between the modelling results and observed outcomes) were ≤1.1% for internal validations (against published studies used to develop the model) and ≤3.7% for external validations

EAG comments
- Analyses are supportive of predictive performance of PRIME T2D model
- Company considered multiple UK populations to compare with, including long term cohorts and cohorts with other GLP-1 RAs
- Applicability to this specific decision problem (i.e. for adults with T2D that is inadequately controlled with 3 or more antidiabetic agents) is uncertain, potentially due to the unavailability of data to provide evidence of predictive performance in this specific population
Model verification against other models/published studies (2)
Comparison of PRIME T2D Model and UKPDS OM2 against ASCEND outcomes

Note: Each point on the graph represents a cumulative incidence value from a model and the corresponding published study value for validation (expressed as cumulative incidence of a given diabetes-related complication). A perfect match between the model and the studies would see all points on the y=x line.

Abbreviations: RMSD, root mean squared deviation; UKPDS, UK Prospective Diabetes Study

Company:
• Notable difference is in terms of mortality estimation, where the PRIME T2D Model was close to the published estimate but the UKPDS OM2 overestimated mortality risk
• The RMSD value for the UKPDS OM2 validation was 3.95% compared with 1.96% with the PRIME T2D Model
• Even when the notable outlier for the UKPDS OM2 model is taken out (i.e. all-cause mortality), the RMSD value was 1.99% with the UKPDS OM2, still a little higher than the PRIME T2D Model.
Model verification against other models/published studies (3)

PRIME T2D Model overall validation

Further validation analysis was also performed against:
- MI, stroke, IHD and heart failure against the EMPA-REG OUTCOME study
- Mortality, MI and stroke against the REWIND study
- MI, stroke and ischaemic heart disease against the LEADER study
- Stroke and heart failure against the Shah et al. cohort study
- First and second MI, first and second stroke, ischaemic heart disease, heart failure, foot ulcer, amputation and renal failure against the LDS UKPDS OM2 dataset
- Published data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which was the derivation cohort for the risk formulae for the BRAVO Model
- The DEVOTE study, the cardiovascular safety trial of insulin degludec

Note: Each point on the graph represents a cumulative incidence value from the PRIME T2D Model and the corresponding published study value for validation (expressed as cumulative incidence of a given diabetes-related complication). A perfect match would see all points on the y=x line.

Abbreviations: IHD, ischemic heart disease; LDS, Lipids in Diabetes Study; MI, myocardial Infarction; UKPDS, The United Kingdom Prospective Diabetes Study
Results run in CORE model
ICERs around £20,000 per QALY

<table>
<thead>
<tr>
<th></th>
<th>PRIME T2D model</th>
<th>CORE Diabetes model</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(tirzepatide vs semaglutide 1.0 mg)</td>
<td>(tirzepatide vs semaglutide 1.0 mg)</td>
</tr>
<tr>
<td>Inc. costs (£)</td>
<td>Incr. LYS</td>
<td>Incr. QALYs</td>
</tr>
<tr>
<td>Tirzepatide 5 mg</td>
<td>708</td>
<td>0.026</td>
</tr>
<tr>
<td>Tirzepatide 10 mg</td>
<td>1,393</td>
<td>0.059</td>
</tr>
<tr>
<td>Tirzepatide 15 mg</td>
<td>2,051</td>
<td>0.080</td>
</tr>
</tbody>
</table>

EAG comments
- Analyses has increased credibility of the PRIME T2D Model
- Unclear how QoL was calculated in case of multiple complications
- CORE Diabetes model predicts less LYS gained but more QALYs gained – company: this could be due to age-adjusting utility values in PRIME T2D model

Has confidence in the PRIME T2D model been improved?

Abbreviations: ICER, incremental cost-effectiveness ratio; LY, life years; QALYs, quality-adjusted life years
**Key issue: Estimating risk of micro- and macrovascular complications (1)**

Company maintains model averaging approach is most appropriate

### Committee comments at ACM1

- Company used model averaging to estimate the risk of micro- and macrovascular complications (which estimated the risk in a range of simulation populations, combining risk equations from 3 different models, and automatically weighing the risk equations for different populations)
- Hypothetically, the company’s approach may be better than using single-risk equations but this is uncertain
- Sensitivity analyses in which a single-risk prediction is selected would help it understand how these approaches compare and the impact on cost-effectiveness estimates

### Company response to ACD

- Model averaging supported by published validation analyses [shown on previous slide]
- Model averaging offers the potential to increase the predictive power of disease models and the ability to average out the influence of background risk modifiers
- Also allows the model to derive weights on a per-patient basis to tailor the overall modelling approach to the target population, and to change this over model time frame, as simulated patients progress from having early to advanced disease
- Scenario analysis using only UKPDS risk equations → results aligned with base case (minor ICER increase)

---

Abbreviations: ICER, incremental cost-effectiveness ratio; UKPDS, UK Prospective Diabetes Study
Key issue: Estimating risk of micro- and macrovascular complications (2)

Average weighting of risk equations over time (tirzepatide 10 mg vs semaglutide 1.0 mg)

Company: UKPDS OM2 risk equations were used predominantly over the first 4–5 years.

Company: Cohort characteristics were more closely matched to the BRAVO derivation population in subsequent years.

Company: As patients with more advanced disease have greater mortality risk, the weighting towards BRAVO risk equations gradually diminishes after year 15 of the simulation.

EAG PRIME T2D Model simulates events according to a predicted risk that lies between the predictions of BRAVO and UKPDS.
**Key issue: Estimating risk of micro- and macrovascular complications (3)**

EAG reassured but some information still missing

### EAG comments

- Reassured that scenario analysis using UKPDS OM2 risk equation only has minor impact on ICER
- Ideally, a scenario analysis including the BRAVO model would also have been provided
- Risk equation selection process based on a systematic literature review and clear inclusion criteria
- Sampling of events in individual patients is driven by a mixture of BRAVO and UKPDS; may be undesirable if these two models substantially differ
- Although the model averaging approach seems to have a good prediction of cardiovascular events, there are many elements that could affect the face validity and applicability of these equations
- Appropriateness of models is not justified in detail e.g. using PROBAST checklist

---

What is the best approach to estimate risk of micro- and macrovascular complications?

Abbreviations: PROBAST, Prediction model Risk Of Bias Assessment Tool; UKPDS, The United Kingdom Prospective Diabetes Study
**Key issue: Treatment intensification**

ICER < £20,000 per QALY but EAG unclear on certain points

**Committee comments at ACM1**

- NICE’s guideline on managing T2D in adults states GLP-1 RAs should only be continued if the person with type 2 diabetes has had a beneficial metabolic response: accordingly, company model assumes people switch to insulin when people’s HbA1c targets are not met
- Clinical practice may deviate from this recommendation: people usually have insulin added on to an existing GLP-1 RA, rather than the GLP-1 RA being stopped
- Scenario analysis assuming treatment is intensified by adding insulin to tirzepatide and GLP-1 RAs would allow it to explore the impact of this deviation on cost-effectiveness estimates

**Company response to ACD**

- Provided scenario analysis where GLP-1 RA therapy (or tirzepatide) was continued after the initiation of basal insulin
- ICER <£20,000 per QALY (marginally higher than base case) for tirzepatide 10mg vs semaglutide 1mg

**EAG comments**

- Unclear how treatment effectiveness was modelled in this scenario, e.g. whether treatment effectiveness was based on the NMA (or only SURPASS-2) and what are company’s assumptions regarding treatment effectiveness of continuation with tirzepatide or GLP-1 RAs

Abbreviations: ACD, appraisal consultation document; GLP-1 RA, Glucagon-Like Peptide-1 receptor agonist; ICER, incremental cost effectiveness ratio; NMA, network meta-analysis; QALY, quality-adjusted life year; T2D, type 2 diabetes; UKPDS, UK Prospective Diabetes Study.
Key issue: Baseline utility value
Company provided scenario analyses using lower baseline utilities

Committee comments at ACM1
- The company's baseline utility value for people with T2D (0.815) was higher than the utility score for the general population at the same age (0.804)
- Preferred the lower baseline utility based on the pooled mean of 3-level version of EQ-5D studies value identified by the EAG (0.772; Redenz et al. 2023)

Company response to ACD
- Noted a recent SLR (Redenz et al. 2023) reported a utility value of 0.815 (95%CI 0.808-0.823) for) based on pooled data from 5-level version of EQ-5D studies people with T2D and no complications
- Provided scenario analysis using a lower baseline utility (0.785) based on Clarke et al. (2002): all tirzepatide doses had ICERs <£20,000 per QALY (lower than base case)
- Also provided scenario analysis EAG preferred value (0.772): all tirzepatide doses had ICERs <£20,000 per QALY (lower than base case)
- Changing the baseline utility has a very modest impact on cost-effectiveness

EAG comments: ICERs increase slightly (and more with higher doses of tirzepatide) when EAG preferred baseline utility used, compared to using 0.785 value

Which baseline utility value should be used?
Key issue: Combining disutilities
Company maintains additive approach is most appropriate

Committee comments at ACM1
- Multiplicative approach is preferred to combine disutilities, in line with the NICE methods manual
- Previous technology appraisals that have used an additive approach were published before the new NICE methods manual applied
- The company did not provide clear rationale for why the multiplicative approach was not appropriate

Company response to ACD
- The disutilities used in modelling were derived as additive disutilities using the EQ-5D instrument
- Gough et al. (2009) concluded that HRQoL decrements associated with T2D and obesity showed no significant interaction and could be assumed to be additive
- Sullivan et al (2011) and Hayes et al. (2016) reported multiple co-morbidities for diabetes and considered it reasonable to treat co-morbidities as independent and add utility decrements
- Provided scenario analysis using a multiplicative approach to combining disutilities for tirzepatide 10mg: had ICERs <£20,000 per QALY (higher than base case)

EAG comments
- Use of additive or multiplicative approach is a matter of judgement
- Scenario increases ICER for tirzepatide 10mg vs. semaglutide 1mg by £3,721 per QALY

Which approach (multiplicative or additive) should be used to combine disutility values?

Abbreviations: HRQoL, health-related quality of life; ICER, incremental cost effectiveness ratio; QALY, quality-adjusted life year
## Company revised base case results

### Tirzepatide 5 mg: Deterministic incremental revised base case results

<table>
<thead>
<tr>
<th></th>
<th>Total costs (£)</th>
<th>Total QALYs</th>
<th>Incremental costs (£)(^a)</th>
<th>Incremental QALYs(^a)</th>
<th>ICER(^a) (£/QALY)</th>
<th>NHB(^a) (QALYs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tirzepatide 5 mg</td>
<td>8.715</td>
<td>8.715</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Dulaglutide 1.5 mg*</td>
<td>8.615</td>
<td>8.615</td>
<td>705</td>
<td>0.100</td>
<td>7,073</td>
<td>0.064</td>
</tr>
<tr>
<td>Dulaglutide 3.0 mg</td>
<td>8.636</td>
<td>8.636</td>
<td>644</td>
<td>0.079</td>
<td>8,182</td>
<td>0.047</td>
</tr>
<tr>
<td>Dulaglutide 4.5 mg</td>
<td>8.657</td>
<td>8.657</td>
<td>628</td>
<td>0.058</td>
<td>10,891</td>
<td>0.026</td>
</tr>
<tr>
<td>Semaglutide 0.5 mg*</td>
<td>8.634</td>
<td>8.634</td>
<td>682</td>
<td>0.081</td>
<td>8,401</td>
<td>0.047</td>
</tr>
<tr>
<td>Semaglutide 1.0 mg</td>
<td>8.673</td>
<td>8.673</td>
<td>708</td>
<td>0.042</td>
<td>16,817</td>
<td>0.007</td>
</tr>
<tr>
<td>Oral semaglutide 7 mg*</td>
<td>8.595</td>
<td>8.595</td>
<td>742</td>
<td>0.120</td>
<td>6,202</td>
<td>0.083</td>
</tr>
<tr>
<td>Oral semaglutide 14 mg</td>
<td>8.642</td>
<td>8.642</td>
<td>719</td>
<td>0.073</td>
<td>9,873</td>
<td>0.037</td>
</tr>
<tr>
<td>Liraglutide 1.2 mg*</td>
<td>8.581</td>
<td>8.581</td>
<td>672</td>
<td>0.134</td>
<td>5,021</td>
<td>0.100</td>
</tr>
<tr>
<td>Liraglutide 1.8 mg</td>
<td>8.600</td>
<td>8.600</td>
<td>-409</td>
<td>0.115</td>
<td>Dominant</td>
<td>0.135</td>
</tr>
</tbody>
</table>

\(^a\) tirzepatide versus comparator; *comparisons considered most relevant by company.

Abbreviations: ICER, incremental cost-effectiveness ratio; NHB, net health benefit; QALYs, quality-adjusted life years.
## Company revised base case results

### Tirzepatide 10 mg: Deterministic incremental revised base case results

<table>
<thead>
<tr>
<th></th>
<th>Total costs (£)</th>
<th>Total QALYs</th>
<th>Incremental costs a (£)</th>
<th>Incremental QALYs</th>
<th>ICER a (£/QALY)</th>
<th>NHB a (QALYs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tirzepatide 10 mg</td>
<td>8.768</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Dulaglutide 1.5 mg</td>
<td>8.615</td>
<td>1,389</td>
<td>0.153</td>
<td>9,091</td>
<td>0.083</td>
<td></td>
</tr>
<tr>
<td>Dulaglutide 3.0 mg*</td>
<td>8.636</td>
<td>1,329</td>
<td>0.132</td>
<td>10,073</td>
<td>0.065</td>
<td></td>
</tr>
<tr>
<td>Dulaglutide 4.5 mg</td>
<td>8.657</td>
<td>1,312</td>
<td>0.111</td>
<td>11,843</td>
<td>0.045</td>
<td></td>
</tr>
<tr>
<td>Semaglutide 0.5 mg</td>
<td>8.634</td>
<td>1,367</td>
<td>0.134</td>
<td>10,171</td>
<td>0.066</td>
<td></td>
</tr>
<tr>
<td>Semaglutide 1.0 mg*</td>
<td>8.673</td>
<td>1,393</td>
<td>0.095</td>
<td>14,616</td>
<td>0.026</td>
<td></td>
</tr>
<tr>
<td>Oral semaglutide 7 mg</td>
<td>8.595</td>
<td>1,427</td>
<td>0.173</td>
<td>8,254</td>
<td>0.102</td>
<td></td>
</tr>
<tr>
<td>Oral semaglutide 14 mg*</td>
<td>8.642</td>
<td>1,403</td>
<td>0.126</td>
<td>11,140</td>
<td>0.056</td>
<td></td>
</tr>
<tr>
<td>Liraglutide 1.2 mg</td>
<td>8.581</td>
<td>1,356</td>
<td>0.187</td>
<td>7,254</td>
<td>0.119</td>
<td></td>
</tr>
<tr>
<td>Liraglutide 1.8 mg*</td>
<td>8.600</td>
<td>276</td>
<td>0.168</td>
<td>1,642</td>
<td>0.154</td>
<td></td>
</tr>
</tbody>
</table>

a tirzepatide versus comparator; *comparisons considered most relevant by company.

Abbreviations: ICER, incremental cost-effectiveness ratio; NHB, net health benefit; QALYs, quality-adjusted life years.
### Company revised base case results

Tirzepatide 15 mg: Deterministic incremental revised base case results

<table>
<thead>
<tr>
<th></th>
<th>Total costs (£)</th>
<th>Total QALYs</th>
<th>Incremental costs (£)</th>
<th>Incremental QALYs</th>
<th>ICER&lt;sup&gt;a&lt;/sup&gt; (£/QALY)</th>
<th>NHB&lt;sup&gt;a&lt;/sup&gt; (QALYs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tirzepatide 15 mg</td>
<td>---</td>
<td>8.808</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Dulaglutide 1.5 mg</td>
<td>---</td>
<td>8.615</td>
<td>2,047</td>
<td>0.192</td>
<td>10,642</td>
<td>0.090</td>
</tr>
<tr>
<td>Dulaglutide 3.0 mg</td>
<td>---</td>
<td>8.636</td>
<td>1,987</td>
<td>0.171</td>
<td>11,586</td>
<td>0.072</td>
</tr>
<tr>
<td>Dulaglutide 4.5 mg*</td>
<td>---</td>
<td>8.657</td>
<td>1,970</td>
<td>0.150</td>
<td>13,104</td>
<td>0.052</td>
</tr>
<tr>
<td>Semaglutide 0.5 mg</td>
<td>---</td>
<td>8.634</td>
<td>2,025</td>
<td>0.174</td>
<td>11,641</td>
<td>0.073</td>
</tr>
<tr>
<td>Semaglutide 1.0 mg*</td>
<td>---</td>
<td>8.673</td>
<td>2,051</td>
<td>0.135</td>
<td>15,209</td>
<td>0.032</td>
</tr>
<tr>
<td>Oral semaglutide 7 mg</td>
<td>---</td>
<td>8.595</td>
<td>2,085</td>
<td>0.212</td>
<td>9,815</td>
<td>0.108</td>
</tr>
<tr>
<td>Oral semaglutide 14 mg*</td>
<td>---</td>
<td>8.642</td>
<td>2,061</td>
<td>0.166</td>
<td>12,453</td>
<td>0.062</td>
</tr>
<tr>
<td>Liraglutide 1.2 mg</td>
<td>---</td>
<td>8.581</td>
<td>2,014</td>
<td>0.227</td>
<td>8,893</td>
<td>0.126</td>
</tr>
<tr>
<td>Liraglutide 1.8 mg*</td>
<td>---</td>
<td>8.600</td>
<td>934</td>
<td>0.208</td>
<td>4,498</td>
<td>0.161</td>
</tr>
</tbody>
</table>

* tirzepatide versus comparator; *comparisons considered most relevant by company.

Abbreviations: ICER, incremental cost-effectiveness ratio; NHB, net health benefit; QALYs, quality-adjusted life years.
### Deterministic scenario analyses

Clinical drivers and duration of therapy: tirzepatide 10 mg vs semaglutide 1.0 mg

<table>
<thead>
<tr>
<th>No.</th>
<th>Scenario*</th>
<th>Incremental costs (£)</th>
<th>Incremental QALYs</th>
<th>ICER (£/QALY gained)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Company revised base case</strong></td>
<td>1,393</td>
<td>0.095</td>
<td>14,616</td>
</tr>
<tr>
<td>1</td>
<td>Direct head-to-head results from SURPASS-2</td>
<td>1,103</td>
<td>0.092</td>
<td>12,019</td>
</tr>
<tr>
<td>2</td>
<td>Using only UKPDS risk equations</td>
<td>1,355</td>
<td>0.087</td>
<td>15,521</td>
</tr>
<tr>
<td>3</td>
<td>GLP-1 RAs and tirzepatide continued (while adding insulin)</td>
<td>1,838</td>
<td>0.125</td>
<td>14,720</td>
</tr>
<tr>
<td>4</td>
<td>Lower baseline utility value for people with T2D (0.785)</td>
<td>1,393</td>
<td>0.100</td>
<td>13,902</td>
</tr>
<tr>
<td>5</td>
<td>Lower baseline utility value for people with T2D (0.772)</td>
<td>1,393</td>
<td>0.099</td>
<td>14,007</td>
</tr>
<tr>
<td>6</td>
<td>Multiplicative method for combining disutilities</td>
<td>1,393</td>
<td>0.076</td>
<td>18,337</td>
</tr>
<tr>
<td>7</td>
<td>Including diarrhoea disutility</td>
<td>1,393</td>
<td>0.093</td>
<td>14,978</td>
</tr>
</tbody>
</table>

*Source: Company response to ACD

Abbreviations: GLP-1 RAs, Glucagon-like peptide-1 receptor agonists; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years; T2D, type 2 diabetes; UKPDS, UK Prospective Diabetes Study
Thank you.